IDEXX Laboratories (IDXX) Q3 2025 Investor Summary
IDEXX reported strong financial performance for the period ended September 30, 2025, highlighted by robust double-digit revenue growth and improved operating leverage, despite margin pressure in one segment.
Financial Highlights (Q3/9M 2025) Total Revenue grew 13.3% in Q3 (\(1.105B) and 9% year-to-date (\)3.213B). Net Income increased 21% over nine months (\(811.3M), leading to a 24% growth in Diluted EPS (\)9.99 for 9M). Total Gross Margin slightly improved to 61.8%, supported by strong recurring revenue volumes and pricing. The LPD seg
...